Peter Fong
Overview
Explore the profile of Peter Fong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pao A, Shahzad S, Song S, Ganesan C, Conti S, Leppert J, et al.
Kidney Med
. 2023 Jul;
5(7):100670.
PMID: 37492113
No abstract available.
2.
Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, et al.
Br J Cancer
. 2023 Feb;
128(8):1418-1428.
PMID: 36797356
Background: Many patients do not respond or eventually relapse on treatment with programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors due to secondary or acquired resistance; therefore, there...
3.
Fong P, Wusirika R, Rueda J, Raphael K, Rehman S, Stack M, et al.
Kidney Int Rep
. 2022 Sep;
7(12):2608-2616.
PMID: 36120391
Introduction: Causes of secondary oxalate nephropathy include enteric dysfunction and excessive intake of oxalate or oxalate precursors. During the COVID-19 pandemic, there has been a dramatic rise in sales of...
4.
Hemnes A, Rathinasabapathy A, Austin E, Brittain E, Carrier E, Chen X, et al.
Eur Respir J
. 2018 Jun;
51(6).
PMID: 29903860
Pulmonary arterial hypertension (PAH) is a deadly disease with no cure. Alternate conversion of angiotensin II (AngII) to angiotensin-(1-7) (Ang-(1-7)) by angiotensin-converting enzyme 2 (ACE2) resulting in Mas receptor (Mas1)...
5.
Liu Y, Sun L, Fong P, Yang J, Zhang Z, Yin S, et al.
Oncotarget
. 2017 Feb;
8(12):19712-19722.
PMID: 28160561
It is well known that abnormal DNA methylations occur frequently in kidney cancer. However, it remains unclear exactly which types of DNA methyltransferases (DNMT) contribute to the pathologies of kidney...
6.
Zhang Y, Guo Z, Li M, Fong P, Zhang J, Zhang C, et al.
PLoS One
. 2015 Oct;
10(10):e0141142.
PMID: 26512901
Currently, the clinical management of visceral pain remains unsatisfactory for many patients suffering from this disease. While preliminary animal studies have suggested the effectiveness of gabapentin in successfully treating visceral...
7.
Wilson M, Fong P, Mesnage S, Chrystal K, Shelling A, Payne K, et al.
Gynecol Oncol
. 2015 May;
138(2):285-91.
PMID: 26003143
Unlabelled: Optimal management of women with early stage granulosa cell tumours (GCT) presents a management conundrum - they have excellent prognosis but a third will relapse. Advances uncovering the molecular...
8.
Lawrenson R, Lao C, Obertova Z, Brown C, Holmes M, Tyrie L, et al.
Oncology
. 2014 Nov;
88(3):157-63.
PMID: 25402412
Objective: This study aims to (1) characterise men diagnosed with metastatic prostate cancer, (2) describe their management and (3) look at their survival. Methods: We identified patients registered with prostate...
9.
Lawrenson R, Obertova Z, Brown C, Fong P, Tyrie L, Scott N, et al.
J Cancer
. 2014 Feb;
5(3):214-20.
PMID: 24563676
Purpose: To assess the patterns of use of androgen deprivation therapy (ADT) and chemotherapeutic agents in New Zealand men with prostate cancer. Methods: Men diagnosed with prostate cancer between 2006...
10.
de Bono J, Piulats J, Pandha H, Petrylak D, Saad F, Aparicio L, et al.
Clin Cancer Res
. 2014 Feb;
20(7):1925-34.
PMID: 24536060
Purpose: Figitumumab is a human IgG2 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), with antitumor activity in prostate cancer. This phase II trial randomized chemotherapy-naïve men with progressing...